With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, shareholders are doubtlessly wondering whether the stock's decline is finished, or if it's just getting started.

With the naming of a new chief technology officer (CTO) on August 9 and a new CEO on September 5, at a minimum investors can have confidence that something about the company's strategy is going to change. But it's also easy to envision a failed attempt at a turnaround.

So let's ask whether the worst is over given what we know right now. 

Continue reading

Source Fool.com